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Abstract This randomised, open-label, two-way cross-
over study compared the coefficient of variance (CV) of
fasting and postprandial blood glucose (FBG and PPBG)
with insulin glargine (glargine) versus neutral protamine
Hagedorn (NPH) insulin treatment in patients with Type 2
diabetes (T2DM). Patients (N = 20) on oral antidiabetic
drugs (OADs) were treated with NPH (at bedtime) or
glargine (at dinnertime) for 12 weeks of each cross-over
treatment period; OADs were continued. The FBG CV was
calculated from self-monitored BG values and PPBG using
venous blood samples, or continuous glucose monitoring
system (CGMS). Both insulins provided similar improve-
ments in glycaemic control; however, PPBG was
significantly lower after a standard meal test (performed at
13:00 h the day after insulin injection) with glargine versus
NPH (p = 0.02). Thirteen versus 15 patients experienced
C1 episode of hypoglycaemia with glargine versus NPH.
The results suggest that glargine plus OADs is more
effective in reducing PPBG fluctuations during the day
than NPH plus OADs.
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Introduction
Type 2 diabetes mellitus is a progressive disease in which
good glycaemic control is essential to prevent or delay the
onset of microvascular or macrovascular complications [1].
Continuous glucose monitoring system (CGMS) determi-
nations show that standard measurements of glycaemic
control underestimate the occurrence of hyperglycaemia in
real-life in Type 2 diabetes mellitus. Given the microvas-
cular and macrovascular damage caused by fasting and
postprandial hyperglycaemia, CGMS provides an excellent
tool to evaluate alternative therapeutic strategies to reduce
hyperglycaemia blood glucose (BG) excursions [2].
A recent study, under real-life conditions found that the
24-h pharmacodynamic profile of insulin glargine was
associated with better CGMS BG profiles with smaller BG
excursions during the day compared with neutral protamine
Hagedorn (NPH) insulin [3], and a similar study found that
switching from NPH insulin to insulin glargine also
resulted in improved CGMS profiles [4]. Diet and exercise
are initially recommended to improve glycaemic control;
however, over time this strategy is usually insufficient to
maintain glycaemic control, necessitating the introduction
of oral antidiabetic drugs (OADs) [5]. As the disease
progresses, management with OADs alone becomes
increasingly difficult and the addition of insulin therapy is
required [6].
Insulin glargine (LANTUS, sanofi-aventis, Paris, France)
is a long-acting human insulin analogue with a smooth
action profile and no pronounced peak in action [7] that
more closely mimics endogenous basal insulin to provide
24-h cover. Insulin glargine is also associated with a
reduced risk of hypoglycaemia compared with the tradi-
tionally used, intermediate-acting, NPH insulin [8].
Although the effect of insulin glargine on fasting blood
Results from this study have been presented as a poster at the
American Diabetes Association annual congress 2007 (Diabetes
2007; 56[Suppl 1]: A148 [Abstract 555-P]).
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glucose (FBG) is well characterised in Type 2 diabetes
mellitus, less is known about its effects on postprandial
glucose handling. Therefore, the aim of the present study
was to determine either by CGMS or by venous plasma
glucose excursion measurement the relative impact of
insulin glargine and NPH insulin on FBG and postprandial
glucose handling after a mixed meal in patients with Type
2 diabetes mellitus.
Here, we report results of a pilot study of insulin glar-
gine versus NPH insulin, both in combination with OADs,
in a two-way cross-over study to determine their effects on
glucose variability after 12 weeks of treatment.
Methods
Objectives
The primary objective of this study was to evaluate the
coefficient of variability (CV) of FBG calculated from self-
monitored blood glucose (SMBG) values.
The secondary objectives of the study included: gly-
caemic control (including measurements of glycated
haemoglobin [HbA1c] and FBG levels); hypoglycaemia;
changes in body weight, final insulin dose and lipid profile;
and profiles of patients that best fitted each of the algo-
rithms with the dependent variable of change in HbA1c and
independent variables, such as age, gender, race, tobacco
use, diabetes complications, initial HbA1c, initial weight,
duration of diabetes mellitus, general education and dia-
betes education. Safety was assessed by the monitoring of
adverse events and other routine laboratory parameters.
Study design
This was an open-label, national, single-centre, random-
ised, controlled, two-way cross-over exploratory study.
The study comprised a 1-week run-in phase, followed by
two 12-week treatment phases and a 2-week safety follow-
up phase (Fig. 1).
Study endpoints
The primary endpoint was FBG CV calculated from SMBG
values obtained during the last 4 weeks before Visit (V)3
(end of Treatment Phase 1) and V4 (end of Treatment
Phase 2). The secondary endpoints were glycaemic control,
as measured by HbA1c, FBG, insulin and C-peptide. In
addition, glycaemic control was measured by the glucose
levels after a standard meal test determined from venous
blood samples or using a CGMS (Glucoday, A.Menarini
Diagnostics, Florence, Italy). Other parameters investi-
gated were changes in urinary albumin-to-creatinine ratio;
changes in lipid profiles (serum total cholesterol, low-
density lipoprotein cholesterol, high-density lipoprotein
cholesterol and triglycerides); frequency of hypoglycae-
mia; general safety and any adverse events reported by
patients at each visit; and changes in weight and final
insulin dose as documented throughout treatment cycles.
The analysis of HbA1c, plasma insulin, C-peptide, gluca-
gon and free fatty acids was performed at Exacta Lab
(Verona, Italy).
Patients
The primary inclusion criteria included male or female
patients C45 years old with a diagnosis of Type 2 diabetes
mellitus (duration C5 years); treatment with OADs in
fixed combination (glibenclamide [2.5 mg] ? metformin
[400 mg]; two or three tablets per day) at a stable dose in the
last 3 months; HbA1c C8 and B11%; body mass index[27
and\35 kg/m2; and willingness and ability to inject insulin
and perform SMBG. The primary exclusion criteria included
patients diagnosed with Type 1 insulin-dependent diabetes
mellitus; patients with fasting C-peptide levels\1 ng/ml (to
potentially exclude patients with latent autoimmune diabetes
of adults); cardiac status New York Heart Association III–
IV; impaired renal function as shown by (but not limited to)
serum creatinine C1.5 mg/dl for males or C1.4 mg/dl for
females; and planned pregnancy, pregnant or lactating
females. The study was conducted in accordance with the
Fig. 1 Study design and visit
schedule. V visit, pts patients,
OAD oral antidiabetic drugs,
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Declaration of Helsinki. Approval by an institutional ethics
committee was obtained. All patients provided written
informed consent prior to study entry.
Study protocol
After a standard clinical evaluation (V1), eligibility was
confirmed and patients were given standardised diet
instructions at study entry. At V2 (baseline), patients were
randomised to either Sequence A (insulin glargine fol-
lowed by NPH insulin) or Sequence B (NPH insulin
followed by insulin glargine) (Fig. 1). Study drugs were
crossed over after 12 weeks of treatment (V3), followed by
a fourth visit (V4) performed at the end of the second 12-
week treatment cycle. A final follow up (V5) was under-
taken 2 weeks after the end of the second 12-week
treatment phase (Fig. 1). The starting insulin glargine/NPH
insulin dose was 10 IU/day and was titrated every 3 days
according to SMBG levels (target FBG: \100 mg/dl),
using a modified algorithm (Table 1) based on the Treat-to-
Target study [9].
At V2, V3 and V4, participants were fitted with the
CGMS device and underwent a mixed meal test, com-
prising 350 kCal (55% carbohydrates, 26% lipids, 19%
proteins) at 13:00 h. Venous blood samples were taken
before the meal and 30, 60 and 120 min after the end of the
meal, in addition to CGMS monitoring. Throughout the
study, SMBG was performed by patients using a glucom-
eter stick test. Measurements of glycaemia in the 48 h after
V2, V3 and V4 were performed by CGMS.
Statistical analysis
The efficacy and safety analyses were performed in the
intent-to-treat population. Descriptive summary statistics
(number of patients, mean, standard deviation, minimum,
maximum) were provided for quantitative variables,
while frequency (absolute and relative) distributions were
provided for categorical variables. The continuous vari-
ables recorded at V2, V3 and V4 were analysed using an
analysis of variance (ANOVA) according to a cross-over
design, with period and treatment effect. Multiple com-
parisons were calculated for the general mean of the
baseline insulin glargine and NPH insulin values. The
comparisons were performed compared with the baseline
mean and between treatments and are reported with the
corresponding 95% confidence interval (CI). For each
parameter recorded during the meal test, the area under
the curve (AUC) adjusted for the basal value (time 0)
was calculated according to the trapezoidal rule and
analysed with the same cross-over model used in the
ANOVA applied to the main parameters. Multiple




Twenty-one patients were randomised to receive the
assigned treatment, of whom ten were assigned to
Sequence A (insulin glargine followed by NPH insulin) and
11 were assigned to Sequence B (NPH insulin followed by
insulin glargine). One patient assigned to Sequence A
discontinued the study at V2 owing to consent withdrawal.
Therefore, 20 patients completed the total study period
(9 in Sequence A and 11 in Sequence B). The baseline
characteristics were similar between the treatment groups
(Table 2).
Table 1 Insulin titration algorithm








The starting insulin glargine/NPH insulin dose was 10 U/IU per day.
The dose of insulin glargine/NPH insulin was to be titrated every
3 days according to the SMBG level, based on the mean FBG value
over the last 2 days. Titration was performed using the algorithm
presented in Table 1. Up-titration was to be stopped temporarily for
1 week in the event of severe hypoglycaemia, unless there was an
explanation for the event (e.g. omission of a meal). Insulin glargine
was to be administered at dinnertime; NPH insulin was to be
administered at bedtime
NPH neutral protamine Hagedorn, SMBG self-monitored blood glu-
cose, FBG fasting blood glucose
Table 2 Baseline characteristics of 20 patients completed
Characteristic
Males/females (n [%]) 14 (70)/6 (30)
Age (years) 59.4 ± 8.2
Weight (kg) 82.7 ± 8.7
Body mass index (kg/m2) 29.5 ± 2.0
HbA1c (%) 9.3 ± 1.4
Fasting blood glucose (mg/dl) 203.6 ± 58.3
All data are mean ± standard deviation unless otherwise stated
HbA1c haemoglobin A1c
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Glycaemic control
Over the duration of the study, the decrease in FBG values
was significant for both study therapies (p \ 0.0001 for
both) with no significant differences between the two insu-
lins (p = 0.95) (Fig. 2a). HbA1c decreased significantly with
both insulin glargine (mean ± standard deviation [SD]:
-1.7 ± 1.6%) and NPH insulin (-1.6 ± 1.6%) compared
with baseline (p \ 0.0001 for both) (Fig. 2b). The mean
amplitude of glucose excursions (MAGE) index measured in
the SMBG tended to improve between baseline and endpoint
with both insulin glargine (-17.0 mg/dl; 95% CI: -34.5,
0.6 mg/dl; p = 0.058) and with NPH insulin (-13.1 mg/dl;
95% CI: -31.4, 5.3 mg/dl; p = 0.152), but there was no
difference between the two insulins (p = 0.603). Mean daily
BG (MDBG) measured in the SMBG improved significantly
between baseline and endpoint with both insulin glargine
(-40.9 mg/dl; 95% CI: -57.0, -24.8 mg/dl; p \ 0.0001)
and with NPH insulin (-43.9 mg/dl; 95% CI: -59.9,
-27.8 mg/dl; p \ 0.0001): there were no differences
between the two insulins (p = 0.701).
Meal test
The CGMS-determined post-meal test BG profile revealed a
lower BG excursion with insulin glargine than with NPH
insulin (p \ 0.05 at 5-h post-meal test and p \ 0.01 at 6-h
post-meal test; Fig. 3a). In response to the standard meal
test, postprandial BG control was better overall with insulin
glargine, with a significantly lower AUC at endpoint
(p = 0.02) compared with NPH insulin (Fig. 3b). The
plasma insulin AUC decreased between baseline and end-
point with both insulin glargine (-61.5 mU/l min; 95% CI:
-97.2, -25.7 mU/l min; p = 0.002) and NPH insulin
(-31.8 mU/l min; 95% CI: -66.5, 2.9 mU/l min; p =
0.070), the magnitude of which tended to be greater with
insulin glargine, although this was not significant (p =
0.109). The plasma glucagon AUC (lg/l min) was similar
with insulin glargine and NPH insulin (mean ± SD:
148.7 ± 12.6 vs. 153.5 ± 12.4 lg/l min; p = 0.3682), and
was unchanged from baseline (146.4 ± 12.3 lg/l min;
p [ 0.05 for both). The plasma C-peptide AUC increased
between baseline and endpoint with both insulin glargine
(?17.6 lg/l min; 95% CI: -3.4, 38.7 lg/l min; p = 0.096)
and with NPH insulin (?39.1 lg/l min; 95% CI: 16.0,
62.2 lg/l min; p = 0.002). Although the change tended to be
greater with NPH insulin, this was not significant (p = 0.090).
Insulin therapy
The total daily dose at endpoint was 28.8 U versus 34.7 IU
for insulin glargine versus NPH insulin, respectively.
Fig. 2 a Fasting blood glucose
as measured by self-monitoring
at baseline and at endpoint.
Results are means ± coefficient
of variation. CV coefficient of
variation, FBG fasting blood
glucose, NPH neutral protamine
Hagedorn. b HbA1c levels
across both study drugs. HbA1c
haemoglobin A1c, NPH neutral
protamine Hagedorn;
**p \ 0.01 versus baseline
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Hypoglycaemia and safety
Thirteen insulin glargine-treated patients and 15 NPH
insulin-treated patients experienced at least one episode of
hypoglycaemia during treatment. Of those patients receiving
insulin glargine, four patients had one episode, three patients
had two episodes, two patients had three episodes and four
patients had more than five episodes of hypoglycaemia.
Among patients receiving NPH insulin, one patient had one
episode, two patients had two episodes, three patients had
three episodes, two patients had five episodes and seven
patients had more than five episodes. None of the episodes in
either treatment group was considered to be severe. Overall,
the incidence of hypoglycaemia was lower with insulin
glargine versus NPH insulin (1.04 vs. 2.12 episodes/patient
per month).
Three patients experienced at least one adverse event
during treatment with insulin glargine. None of the events
was considered to be related to study drug.
Other secondary parameters
No significant changes were observed in either treatment
group at any time point for other secondary parameters,
including body weight, haematology or blood chemistry.
Discussion
This study demonstrates that the initiation of insulin ther-
apy with OADs effectively improves glycaemic control in
patients with Type 2 diabetes mellitus. Both insulins
achieved similar improvements in FBG, MAGE, MDBG
and HbA1c over 12 weeks of treatment, with comparable
improvements in within-patient variability, and supporting
the perception that there was no clinically different impact
on glycaemic control. Aside from the overall measures of
glycaemic control, participants in our study also underwent
standard meal tests (at 13:00 h), at baseline and after each
12-week treatment period.
Although both treatments provided comparable impro-
vements in glycaemic control, blood glucose AUCs were
significantly higher with NPH insulin (administered once
daily at bedtime) compared with insulin glargine (admin-
istered once daily at dinnertime). Taking into account the
cross-over study design, these results indicate that insulin
glargine may provide better control of the postprandial
glucose levels, as measured by the meal test. This finding
may be related to a waning of the effect of NPH insulin,
which was administered at bedtime (approximately
22:00 h), owing to its duration of action of 12–18 h [7] and
rate of subcutaneous absorption [10]. It may be that, if
Fig. 3 a Continuous glucose
monitoring system profiles in
response to the meal test. BL
before lunch, NS non-
significant, AL after lunch, NPH
neutral protamine Hagedorn.
b Meal test blood glucose levels
after each treatment. Results are
means ± coefficient of
variation. AUC area under the
curve, CV coefficient of
variation, NPH neutral
protamine Hagedorn
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NPH insulin had been administered twice daily, the post-
meal glucose levels may have more closely matched those
achieved with insulin glargine.
Owing to the relatively small sample size of our study
(20 patients completed both arms of the study), and the fact
that there is some evidence for a carry-over effect after
cross-over, results presented here should be interpreted
with caution. However, the results of this pilot study
warrant prospective evaluation in a larger population of
patients, which could be powered based on the magnitude
of differences between the two treatment groups. Further
studies are warranted using a larger patient population to
better compare the differences in post-meal glucose han-
dling between insulin glargine and NPH insulin to better
define the qualitative aspect of each HbA1c level detected
at the end of each treatment. It is clear from our results that
insulin glargine provides significant improvements in gly-
caemic control at lunchtime compared with NPH insulin.
Nevertheless, management of the fasting and postprandial
components of glycaemic control is important owing to
their contributions to overall glycaemic control [11]. The
introduction of short-acting insulin at mealtimes may help
these patients achieve their glycaemic goals. It may be that,
with better understanding of the impact of insulin glargine
on postprandial glycaemia, the administration of prandial
insulin at the meal associated with the highest glucose
excursion may provide the required improvements in gly-
caemic control [12]. Indeed, this was partly evaluated in
the Orals Plus insulin glulisine and insulin glargine
(OPAL) study, in which patients treated with insulin glar-
gine plus OADs were randomised to receive once-daily
insulin glulisine at either breakfast or the main meal
(defined as the meal associated with the largest prandial
glucose excursion). In that study, the improvements in
glycaemic control were comparable in both treatment
groups (equivalence of breakfast versus main meal
administration was shown), but there was a tendency for
more patients in the main meal versus breakfast group to
reach HbA1c B6.5% (33.8 vs. 27.8%) [13]. Accordingly,
future studies could evaluate the postprandial glucose
excursions using CGMS in a ‘real-life’ situation of patients
treated with insulin glargine at dinnertime or bedtime. The
lower blood glucose fluctuations during the day with
glargine versus NPH can be detected by additional quali-
tative measurements of glycaemic control or new CGMS
measurements on top of traditional quantitative HbA1c
values [14]. In fact, a recent study conducted in patients
with diabetes by Nathan and colleagues found that a linear
relationship exists between HbA1c levels and average
glucose (AG), as measured by CGMS in a clinically rele-
vant range of glycaemia [15].
The control of glycaemic levels by limiting the magni-
tude of hyperglycaemia spikes (Fig. 3a) or hypoglycaemia
troughs in the management of insulin therapy of Type 2
diabetes mellitus patients can prevent the development of
long-term diabetes complications, such as cardiovascular
disease, nephropathy, retinopathy and neuropathy [16–18].
The quantitative measurement of HbA1c levels is a widely
used, reliable, simple and easy method for assessing gly-
caemic control [17, 19, 20]. Indeed, current diabetes
guidelines have delineated target HbA1c levels to prevent
long-term diabetic complications [16–18, 21]. However,
measuring glycaemic control by utilising standard mea-
surements of HbA1c levels can limit, by masking the true
nature of glycaemic variability, the clear interpretation of
biological efficiency of insulin treatment from a long-term
perspective [22, 23] for people with diabetes and especially
for those with Type 2 diabetes mellitus [24].
In conclusion, the results indicate that adding insulin
glargine to existing OADs is more effective in reducing
postprandial BG fluctuations during the day compared with
NPH insulin plus OADs, with a lower incidence of
hypoglycaemia.
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